839 related articles for article (PubMed ID: 25593184)
1. Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors.
Flynn RL; Cox KE; Jeitany M; Wakimoto H; Bryll AR; Ganem NJ; Bersani F; Pineda JR; Suvà ML; Benes CH; Haber DA; Boussin FD; Zou L
Science; 2015 Jan; 347(6219):273-7. PubMed ID: 25593184
[TBL] [Abstract][Full Text] [Related]
2. Genetic Inactivation of ATRX Leads to a Decrease in the Amount of Telomeric Cohesin and Level of Telomere Transcription in Human Glioma Cells.
Eid R; Demattei MV; Episkopou H; Augé-Gouillou C; Decottignies A; Grandin N; Charbonneau M
Mol Cell Biol; 2015 Aug; 35(16):2818-30. PubMed ID: 26055325
[TBL] [Abstract][Full Text] [Related]
3. Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway.
Lovejoy CA; Li W; Reisenweber S; Thongthip S; Bruno J; de Lange T; De S; Petrini JH; Sung PA; Jasin M; Rosenbluh J; Zwang Y; Weir BA; Hatton C; Ivanova E; Macconaill L; Hanna M; Hahn WC; Lue NF; Reddel RR; Jiao Y; Kinzler K; Vogelstein B; Papadopoulos N; Meeker AK;
PLoS Genet; 2012; 8(7):e1002772. PubMed ID: 22829774
[TBL] [Abstract][Full Text] [Related]
4. PML induces compaction, TRF2 depletion and DNA damage signaling at telomeres and promotes their alternative lengthening.
Osterwald S; Deeg KI; Chung I; Parisotto D; Wörz S; Rohr K; Erfle H; Rippe K
J Cell Sci; 2015 May; 128(10):1887-900. PubMed ID: 25908860
[TBL] [Abstract][Full Text] [Related]
5. Suppression of the alternative lengthening of telomere pathway by the chromatin remodelling factor ATRX.
Clynes D; Jelinska C; Xella B; Ayyub H; Scott C; Mitson M; Taylor S; Higgs DR; Gibbons RJ
Nat Commun; 2015 Jul; 6():7538. PubMed ID: 26143912
[TBL] [Abstract][Full Text] [Related]
6. ATRX loss induces multiple hallmarks of the alternative lengthening of telomeres (ALT) phenotype in human glioma cell lines in a cell line-specific manner.
Brosnan-Cashman JA; Yuan M; Graham MK; Rizzo AJ; Myers KM; Davis C; Zhang R; Esopi DM; Raabe EH; Eberhart CG; Heaphy CM; Meeker AK
PLoS One; 2018; 13(9):e0204159. PubMed ID: 30226859
[TBL] [Abstract][Full Text] [Related]
7. Probing PML body function in ALT cells reveals spatiotemporal requirements for telomere recombination.
Draskovic I; Arnoult N; Steiner V; Bacchetti S; Lomonte P; Londoño-Vallejo A
Proc Natl Acad Sci U S A; 2009 Sep; 106(37):15726-31. PubMed ID: 19717459
[TBL] [Abstract][Full Text] [Related]
8. hRad21 overexpresses and localizes to the ALT-associated promyelocytic leukemia body in ALT cells.
Zhao B; Wang ZJ; Yi BQ; Ma HC; Xu HM
Cancer Biol Ther; 2010 Jun; 9(12):978-83. PubMed ID: 20364118
[TBL] [Abstract][Full Text] [Related]
9. Topoisomerase IIIalpha is required for normal proliferation and telomere stability in alternative lengthening of telomeres.
Temime-Smaali N; Guittat L; Wenner T; Bayart E; Douarre C; Gomez D; Giraud-Panis MJ; Londono-Vallejo A; Gilson E; Amor-Guéret M; Riou JF
EMBO J; 2008 May; 27(10):1513-24. PubMed ID: 18418389
[TBL] [Abstract][Full Text] [Related]
10. Functional Loss of
Graham MK; Kim J; Da J; Brosnan-Cashman JA; Rizzo A; Baena Del Valle JA; Chia L; Rubenstein M; Davis C; Zheng Q; Cope L; Considine M; Haffner MC; De Marzo AM; Meeker AK; Heaphy CM
Mol Cancer Res; 2019 Dec; 17(12):2480-2491. PubMed ID: 31611308
[TBL] [Abstract][Full Text] [Related]
11. FANCM, BRCA1, and BLM cooperatively resolve the replication stress at the ALT telomeres.
Pan X; Drosopoulos WC; Sethi L; Madireddy A; Schildkraut CL; Zhang D
Proc Natl Acad Sci U S A; 2017 Jul; 114(29):E5940-E5949. PubMed ID: 28673972
[TBL] [Abstract][Full Text] [Related]
12. Mutant IDH1 Cooperates with ATRX Loss to Drive the Alternative Lengthening of Telomere Phenotype in Glioma.
Mukherjee J; Johannessen TC; Ohba S; Chow TT; Jones L; Pandita A; Pieper RO
Cancer Res; 2018 Jun; 78(11):2966-2977. PubMed ID: 29545335
[TBL] [Abstract][Full Text] [Related]
13. Telomere maintenance by telomerase and by recombination can coexist in human cells.
Cerone MA; Londono-Vallejo JA; Bacchetti S
Hum Mol Genet; 2001 Sep; 10(18):1945-52. PubMed ID: 11555631
[TBL] [Abstract][Full Text] [Related]
14. Loss of wild-type ATRX expression in somatic cell hybrids segregates with activation of Alternative Lengthening of Telomeres.
Bower K; Napier CE; Cole SL; Dagg RA; Lau LM; Duncan EL; Moy EL; Reddel RR
PLoS One; 2012; 7(11):e50062. PubMed ID: 23185534
[TBL] [Abstract][Full Text] [Related]
15. RNaseH1 regulates TERRA-telomeric DNA hybrids and telomere maintenance in ALT tumour cells.
Arora R; Lee Y; Wischnewski H; Brun CM; Schwarz T; Azzalin CM
Nat Commun; 2014 Oct; 5():5220. PubMed ID: 25330849
[TBL] [Abstract][Full Text] [Related]
16. Telomere dysfunction and activation of alternative lengthening of telomeres in B-lymphocytes infected by Epstein-Barr virus.
Kamranvar SA; Chen X; Masucci MG
Oncogene; 2013 Dec; 32(49):5522-30. PubMed ID: 23708666
[TBL] [Abstract][Full Text] [Related]
17. Cancer-associated SMARCAL1 loss-of-function mutations promote alternative lengthening of telomeres and tumorigenesis in telomerase-negative glioblastoma cells.
Liu H; Xu C; Diplas BH; Brown A; Strickland LM; Yao H; Ling J; McLendon RE; Keir ST; Ashley DM; He Y; Waitkus MS
Neuro Oncol; 2023 Sep; 25(9):1563-1575. PubMed ID: 36689342
[TBL] [Abstract][Full Text] [Related]
18. Telomere elongation chooses TERRA ALTernatives.
Arora R; Azzalin CM
RNA Biol; 2015; 12(9):938-41. PubMed ID: 26158306
[TBL] [Abstract][Full Text] [Related]
19. Alternative lengthening of telomeres is a self-perpetuating process in ALT-associated PML bodies.
Zhang JM; Genois MM; Ouyang J; Lan L; Zou L
Mol Cell; 2021 Mar; 81(5):1027-1042.e4. PubMed ID: 33453166
[TBL] [Abstract][Full Text] [Related]
20. Lack of TRF2 in ALT cells causes PML-dependent p53 activation and loss of telomeric DNA.
Stagno D'Alcontres M; Mendez-Bermudez A; Foxon JL; Royle NJ; Salomoni P
J Cell Biol; 2007 Dec; 179(5):855-67. PubMed ID: 18056407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
